阿布昔替尼片有几种规格?

Abxitinib tablets are a new JAK inhibitor for atopic dermatitis. Its specification selection, contraindications and precautions are of great significance to the rational clinical use of the drug. This article will systematically elaborate on these three key aspects to help medical professionals and patients fully understand the use characteristics of this drug.

Abxitinib tablets are available in several specifications

It is divided into multiple specifications according to different dosages to meet the treatment needs of different patients. Understanding the characteristics of these specifications is crucial to formulating individualized treatment plans.

Conventional treatment specifications

The common specification of Abxitinib tablets on the market is 100mg*14 tablets/box, which is suitable for maintenance treatment of most patients with atopic dermatitis. The generic drug produced by Lucius Pharmaceutical Factory in Laos sells for about US$56 per box.

Dose adjustment specifications

According to clinical research data, Abxitinib tablets are available in three single-dose specifications: 50mg, 100mg and 200mg. The 10mg specification is a pink oblong tablet, engraved with the words "10" and "FI"; the 20mg specification is a light yellow oblong tablet, engraved with the words "20" and "FI".

Strength for special groups

For patients with CYP2C19 slow metabolizers, it is recommended to start treatment with the 50 mg strength. Those who use strong CYP2C19 inhibitors also need to adjust the dosage to 50mg to reduce the risk of adverse reactions.

The various specifications of Abxitinib tablets provide flexible choices for clinical treatment, and precise dosing can be implemented according to the specific conditions of the patient.

Contraindications of Abxitinib Tablets

Identifying the contraindications of Abxitinib Tablets plays a key role in preventing serious adverse events. The use of this drug should be strictly avoided in the following cases.

Patients with active infections

Contraindicated in patients with active tuberculosis, hepatitis B, severe bacterial or fungal infections. JAK inhibitors may increase the risk of infection, and infection screening needs to be completed before treatment.

Severe hepatic insufficiency

It is prohibited for use in patients with Child-Pugh Class C hepatic impairment. Severe hepatic impairment may significantly affect drug metabolism and increase the risk of toxicity.

People at high risk of thrombosis

It is contraindicated in patients with a history of deep vein thrombosis or pulmonary embolism. Abxitinib may increase the risk of thrombosis, especially when combined with other risk factors.

Strictly mastering the contraindications of Abxitinib tablets is the first prerequisite to ensure the safety of medication.

Precautions for Abxitinib Tablets

Rational use of Abxitinib Tablets requires attention to a number of important matters, which directly affect the therapeutic effect.

Infection monitoring and management

During treatment, signs of infection need to be closely monitored, and medication should be suspended if shingles occurs; if severe infection occurs, medication must be stopped immediately and anti-infective treatment must be carried out. Vaccinations should be completed before treatment.

Laboratory indicator monitoring

Complete blood cell count needs to be measured before medication and after 4 weeks of treatment. Monitor blood lipid levels and liver function regularly, and take intervention measures if necessary.

Dose adjustment for special groups

Patients with moderate renal impairment need to reduce the dosage; patients with CYP2C19 slow metabolizers should start with 50 mg; dosage needs to be adjusted when combined with strong CYP2C19 inhibitors.

Following the precautions for taking Abxitinib tablets can maximize the therapeutic effect while minimizing the risk of adverse reactions.